A Phase 2 interventional study of IMSA101 and Immune checkpoint inhibitor in Oligoprogressive, sponsored by ImmuneSensor Therapeutics Inc.. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by ImmuneSensor Therapeutics Inc. · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with oligoprogressive solid tumor malignancies after prior anti-cancer therapy.
Patients shall be enrolled in 2 treatment arms as follows:
PULSAR-ICI with or without IMSA101 treatment will be administered to the patients in Cycles 1, 2, and 3, and thereafter only standard of care ICI monotherapy will be administered to all patients. Each treatment cycle will be 28 days in duration for Cycles 1, 2 and 3, then per standard of care monotherapy thereafter based on the product labels of the prescribed ICI.
The study will start with a safety run-in portion at 2 dose levels for the experimental arm, followed by a randomized portion for both treatment arms. The safety run-in shall employ a 3+3 safety run-in component.
All patients will be followed throughout the study for drug tolerability and safety by collecting clinical and laboratory data, including adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria, SAEs, concomitant medications, and vital signs.
All patients will be assessed for anti-tumor efficacy at screening, prior to the end of Cycle 3, and at 8-week intervals thereafter based on radiographic assessments (all outcome measures per RECIST Version 1.1 and iRECIST).
Tumor types and the corresponding treatment combinations to be evaluated will be identified prior to the first patient enrolled.
All patients will continue to receive their assigned treatment throughout the study until the occurrence of disease progression (based on iRECIST), death, or other unacceptable treatment-related toxicity, or until the study is closed by the sponsor.
ImmuneSensor Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acceptable organ and marrow function as defined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PULSAR-ICI + IMSA101
Drug: IMSA101 · Drug: Immune checkpoint inhibitor · Radiation: PULSAR
PULSAR-ICI
Drug: Immune checkpoint inhibitor · Radiation: PULSAR
Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
Also known as: pembrolizumab, nivolumab
1st day of Cycles 1, 2 and 3.
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Anti-tumor Effects
Progression-free rate at 12 months
Time frame: 12 months
Safety and Tolerability
Occurrence of treatment-related adverse events and SAEs
Time frame: 8 months
Anti-tumor Effects
Progression-free at 8-week intervals from 6 months to 8 months.
Time frame: 6 to 8 months
Anti-tumor Effects
Time-to-progression (TTP)
Time frame: upon enrolment through end of study period (8 months)
Anti-tumor Effects
Overall response rate, duration of response, progression-free survival
Time frame: upon enrolment through end of study period (8 months)
Functional Assessment of Cancer Therapy - General (FACT-G) Quality of Life (QoL)
The Functional Assessment of Cancer Therapy - General (FACT-G) is a patient-reported outcome (PRO) assessing health-related quality of life (HRQoL) in individuals with cancer across physical, social/family, emotional, and functional domains. The FACT-G (Version 4) contains 27 items across four subscales. Each item uses a 0-4 Likert scale (0 = Not at all, 4 = Very much), with some items reverse-scored so that higher scores always indicate better quality of life. Physical Well-Being (PWB) - 7 items, score range 0-28 (higher = better physical well-being. Social/Family Well-Being (SWB) - 7 items, score range 0-28 (higher = better social/family well being) Emotional Well-Being (EWB) - 6 items, score range 0-24 (higher = better emotional well-being) Functional Well-Being (FWB) - 7 items, score range 0-28 (higher = better functional well being) Scores provided show average baseline and average post-baseline comparison scores for all patient who completed the FACT-G questionnaire on trial
Time frame: upon enrolment through end of study period (8 months)
Study was terminated early by sponsor due to change in corporate strategy.
| Milestone | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Started | 3 | 11 | 2 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 11 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 |
| Withdrew: Early study termination | 1 | 7 | 2 |
Progression-free rate at 12 months
| Participants | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Anti-tumor Effects | 0 | 0 | 0 |
Occurrence of treatment-related adverse events and SAEs
| Participants | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Safety and Tolerability | 3 | 11 | 2 |
Progression-free at 8-week intervals from 6 months to 8 months.
| Participants | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Progression Free | 1 | 0 | 0 |
| Not evaluable | 1 | 0 | 0 |
Time-to-progression (TTP)
| Participants | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Progressed in 5 months | 1 | 0 | 0 |
| Progressed in 4 months | 0 | 1 | 0 |
| Not evaluable | 2 | 10 | 2 |
Overall response rate, duration of response, progression-free survival
| Participants | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Complete Response | 0 | 0 | 0 |
| Partial Response | 1 | 0 | 0 |
| Stable Disease | 0 | 0 | 0 |
| Progressive Disease | 1 | 1 | 0 |
| Not evaluable | 1 | 10 | 2 |
The Functional Assessment of Cancer Therapy - General (FACT-G) is a patient-reported outcome (PRO) assessing health-related quality of life (HRQoL) in individuals with cancer across physical, social/family, emotional, and functional domains. The FACT-G (Version 4) contains 27 items across four subscales. Each item uses a 0-4 Likert scale (0 = Not at all, 4 = Very much), with some items reverse-scored so that higher scores always indicate better quality of life. Physical Well-Being (PWB) - 7 items, score range 0-28 (higher = better physical well-being. Social/Family Well-Being (SWB) - 7 items, score range 0-28 (higher = better social/family well being) Emotional Well-Being (EWB) - 6 items, score range 0-24 (higher = better emotional well-being) Functional Well-Being (FWB) - 7 items, score range 0-28 (higher = better functional well being) Scores provided show average baseline and average post-baseline comparison scores for all patient who completed the FACT-G questionnaire on trial
| Scores on a scale | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Physical Well Being - Baseline | .95 ± .85 | .79 ± .41 | .71 ± .95 |
| Physical Well Being - post-Baseline | .98 ± .43 | 1.08 ± .44 | — |
| SOCIAL/FAMILY WELL-BEING - Baseline | 3.14 ± 1.44 | 2.84 ± 1.34 | 3.0 ± 1.73 |
| SOCIAL/FAMILY WELL-BEING - Post Baseline | 2.96 ± 1.23 | 2.81 ± 1.31 | — |
| EMOTIONAL WELL-BEING - Baseline | 1.13 ± 1.14 | 1.15 ± 1.14 | 1.32 ± .82 |
| EMOTIONAL WELL-BEING - Post Baseline | 1.10 ± 1.01 | 1.27 ± .79 | — |
| FUNCTIONAL WELL-BEING - Baseline | 2.88 ± .44 | 2.87 ± .21 | 3.29 ± .76 |
| FUNCTIONAL WELL-BEING - Post baseline | 2.93 ± .53 | 2.25 ± .47 | — |
Collected over 8 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Arm (800 mcg) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Experimental Arm (1200 mcg) | 0/11 (0%) | 2/11 (18.2%) | 11/11 (100%) |
| Control Arm | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| Flank PainMusculoskeletal and connective tissue disorders | 1/3 | 0/11 | 0/2 |
| Cerebrovascular accidentNervous system disorders | 1/3 | 0/11 | 0/2 |
| Injection Site ReactionGeneral disorders | 0/3 | 1/11 | 0/2 |
| Hip FractureMusculoskeletal and connective tissue disorders | 0/3 | 1/11 | 0/2 |
| Event | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm |
|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/3 | 1/11 | 0/2 |
| NauseaGastrointestinal disorders | 1/3 | 6/11 | 0/2 |
| Blood alkaline phosphatase increasedInvestigations | 1/3 | 1/11 | 1/2 |
| Blood creatinine increasedInvestigations | 1/3 | 0/11 | 1/2 |
| Blood lactate dehydrogenase decreasedInvestigations | 0/3 | 1/11 | 1/2 |
| VomitingGastrointestinal disorders | 1/3 | 5/11 | 0/2 |
| FatigueGeneral disorders | 1/3 | 4/11 | 0/2 |
| PyrexiaGeneral disorders | 1/3 | 4/11 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 3/11 | 0/2 |
| ChillsGeneral disorders | 1/3 | 1/11 | 0/2 |
| Age, Categorical(Participants) | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 6 | 1 | 8 |
| >=65 years | 2 | 5 | 1 | 8 |
| Sex: Female, Male(Participants) | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm | Total |
|---|---|---|---|---|
| Female | 1 | 5 | 1 | 7 |
| Male | 2 | 6 | 1 | 9 |
| Race (NIH/OMB)(Participants) | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 2 | 9 | 2 | 13 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Experimental Arm (800 mcg) | Experimental Arm (1200 mcg) | Control Arm | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 3 |
| Not Hispanic or Latino | 2 | 9 | 2 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Nov 2024, 16 months.
Results were first posted in May 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: STING Agonist IMSA101
ImmuneSensor Therapeutics Inc.